2024-514853-31-00RecruitingPhase 1
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COR-1389
Source: EU CTIS (euclinicaltrials.eu) · Last updated 20 Aug 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 21 Jun 2024
- Start date
- 10 Sept 2024
- Lead sponsor
- Corteria Pharmaceuticals
- Diseases
- Heart failure, Obesity
- EU CT number
- 2024-514853-31-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 140
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 64 to test the safety and tolerability of COR-1389 and how the body handles it. The record lists healthy participants.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROFIL Institut fuer Stoffwechselforschung GmbH | Neuss | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.